NORWALK, CT., October 9, 2025 /PRNewswire/ — Lifespan Vision Ventures congratulates its portfolio company, Algen Biotechnologies, on the announcement of its multi-target research collaboration with AstraZeneca to advance AI-driven drug discovery in immunology.
The partnership will combine Algen’s cutting-edge functional genomics and machine learning platform with AstraZeneca’s deep scientific expertise and global R&D capabilities. Together, the companies aim to identify and validate novel therapeutic targets for inflammatory and immune-mediated diseases, thereby accelerating the discovery of next-generation drugs.
Harry Robb, Director of Lifespan Vision Ventures, said: “We are delighted to see Algen Biotechnologies reach this important milestone. The team has built a truly differentiated platform that integrates CRISPR-based functional screening with advanced AI analytics to discover disease-relevant biology at scale. This collaboration with AstraZeneca highlights the strength of Algen’s technology and its potential to transform drug discovery.
As an early-stage investor, Lifespan Vision Ventures is proud to support Algen Biotechnologies in its mission to advance transformative therapies that improve outcomes for patients with age-related diseases and extend lifespan.
About Algae Biotechnology
Algen Biotechnologies is a precision therapeutics company redefining drug discovery at the intersection of CRISPR gene modulation and artificial intelligence. Founded by Chun-Hao Huang and Christine Du as a spinout from Nobel laureate Jennifer Doudna’s lab at UC Berkeley, Algen combines deep learning with high-throughput functional genomics to identify new therapeutic targets. Its proprietary end-to-end platform, AlgenBrain™, integrates advanced computational models with scalable, single-cell experimental systems to decode the causal biology of diseases and accelerate the development of next-generation therapies. Algen is headquartered in San Francisco, California.
For more information, visit www.algenbio.com.
About Lifespan Vision Ventures
Lifespan Vision Ventures is a global venture capital firm that invests in early-stage biotechnology and longevity companies developing breakthrough technologies to prevent and treat age-related diseases. The company partners with visionary founders to deliver science-based solutions that promote healthy aging and prolong human vitality.
Contact: info@lifespanvision.com
SOURCE LifeSpan Vision Ventures
